TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy
Open Access
- 23 July 2020
- Vol. 12 (8), 2049
- https://doi.org/10.3390/cancers12082049
Abstract
Loss of p53 promotes vascular endothelial growth factor (VEGF)-A up-regulation and the angiogenic potential of cancer cells. We investigated TP53 somatic mutations in 110 primary gastric adenocarcinomas of two retrospective metastatic series including 48 patients treated with second-line Ramucirumab/Paclitaxel and 62 patients who received first-line chemotherapy with Cisplatin or Oxaliplatin plus 5-Fluorouracil. Missense mutations were classified by tumor protein p53 (TP53) mutant-specific residual transcriptional activity scores (TP53RTAS) and used to stratify patients into two groups: transcriptionally TP53Active and TP53Inactive. The primary endpoint was overall survival (OS). An additional analysis was addressed to measure VEGF/VEGF receptor 2 (VEGFR2) expression levels in relation to the TP53RTAS. In the Ramucirumab/Paclitaxel group, 29/48 (60.4%) patients had TP53 mutations. Ten patients with TP53Inactive mutations showed better OS than carriers of other TP53 mutations. This effect was retained in the multivariate model analysis (Hazard Ratio = 0.29, 95% confidence interval = 0.17–0.85, p = 0.02). In the chemotherapy group, 41/62 (66%) patients had TP53 mutations, and the 11 carriers of TP53Inactive mutations showed the worst OS (Hazard Ratio = 2.64, 95% confidence interval = 1.17–5.95, p = 0.02). VEGF-A mRNA expression levels were significantly increased in TP53Inactive cases. Further studies are warranted to explore the effect of TP53Inactive mutations in different anti-cancer regimens. This information would lead to new tailored therapy strategies for this lethal disease.This publication has 35 references indexed in Scilit:
- Mutant p53 in Cancer: New Functions and Therapeutic OpportunitiesCancer Cell, 2014
- The pharmacological bases of the antiangiogenic activity of paclitaxelAngiogenesis, 2013
- Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathwayBritish Journal of Cancer, 2012
- Integrative genomics viewerNature Biotechnology, 2011
- p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathwayCancer Letters, 2009
- Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?British Journal of Cancer, 2008
- Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGFProceedings of the National Academy of Sciences of the United States of America, 2006
- Reporting Recommendations for Tumor Marker Prognostic StudiesJournal of Clinical Oncology, 2005
- Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysisProceedings of the National Academy of Sciences of the United States of America, 2003
- Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosisNature Medicine, 1996